Vaccine distribution to millions of people and reports of declining rates of COVID-19 infection are generating optimism in the United States that the health crisis and its economic devastation are beginning to retreat before a modern medical technology assault, even as health officials continue to issue warnings that the deadly virus and its variants are still very active (https://ibn.fm/cl8Vk).
Bioscience technology accelerator XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) is now ready to launch its own solution for improving detection of the virus responsible for the worldwide pandemic. The company announced on March 18 that European regulatory officials have approved its point-of-care SARS-CoV-2 (COVID-19) RT-PCR test system, known more simply as “Covid-ID Lab,” as a commercial in vitro diagnostic device (CE-IVD) designed to help industry professionals and government agencies screen for the virus.
Covid-ID Lab was developed by XPhyto’s exclusive German diagnostics development partner, 3a-diagnostics GmbH to be a COVID-19 testing system that is rapid, accurate and portable, granting it marketability as a product with decreased operating costs and increased convenience.
“Our test is one of the fastest PCR-based COVID-19 tests currently approved. With a sample collection to result time of 25 minutes, Covid-ID Lab combines the speed of a rapid screening test with the accuracy of a PCR diagnostic,” XPhyto CEO and Director Hugh Rogers stated (https://ibn.fm/Fi0Mw). “Covid-ID Lab is designed for point-of-care testing, particularly in satellite and small-scale labs, such as transportation hubs, borders, care facilities, schools, pharmacies, and hospitality settings.”
The company announced in February that it had quickly formed a team of expert marketing leaders to launch Covid-ID Lab in anticipation of its approval under internationally agreed-on ISO 13485 quality standards. The market launch team consists of world-class clinical and pharmaceutical executives and service providers who have led company growth in the medical diagnostic industry from inception to over 500 million Euro per year in multinational sales, according to a company news release about the team’s work (https://ibn.fm/plVjO).
Sales rollout of the diagnostic tool is planned for April across Europe and official discussions about distribution and wholesale opportunities are under way with potential partners in the Middle East as well.
“We are extremely fortunate to now have a team with deep expertise in medical diagnostic product commercialization,” Rogers stated. “We are working hard to put the Company in the best possible position to execute on our business strategy.”
XPhyto also is developing an expanded portfolio of oral biosensor screening tests that will help clients detect other bacterial and viral infectious diseases, such as influenza A, group A strep, periodontitis and the H1N1 and H5N1 flu variants responsible for previous pandemics. The company is aiming for its first product launch under the portfolio in late 2021.
XPhyto has research and development operations in North America and Europe but its focus is the European market at this time.
For more information, visit the company’s website at www.XPhyto.com.
NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
According to a recent study, individuals who have used classic psychedelics like LSD or psilocybin…
There is a growing trend in which parents take tiny doses of psychedelics like LSD…
Walter Reed National Military Medical Center officials confirmed they are awaiting a $4.9m grant to…
A new study has found that while all ethnic and racial groups can benefit from…
A new study that is yet to be peer-reviewed has found that rats given psilocybin…
The American embassy in Peru has warned Americans against taking traditional psychedelics like the ayahuasca…